Lake Street maintains Biodesix at Buy, lowers price target to $30 from $40
Lake Street maintained its Buy rating for Biodesix but reduced its price target from $40 to $30, a 25% decrease. The new target suggests a 251.7% upside from the Nov 6 close of $8.53.
How this was made

The 30-second read
Why it matters
The downgrade may trigger short-term price decline, but longer-term catalysts could offset.
Market read
Analyst target cut is a modest but actionable signal for traders monitoring biotech equities.
What to watch
Potential pipeline milestones not reflected in the target revision.
Background
Lake Street Research provides equity research coverage; price target changes influence investor expectations.
Ticker impact
Lake Street lowered Biodesix's price target to $30 from $40, a 25% reduction.
downward pressure as investors price in the reduced target
A 25% target cut signals weaker outlook, likely prompting short-term sell pressure.
Market effects
May weigh on other diagnostic biotech stocks as analysts reassess valuations.
Limited to US biotech sector.
Low
Counterpoint
Target cut could be overreaction; upside remains if upcoming data beats expectations.
Key entities
- Research FirmLake Street Research
Equity research provider issuing the price target revision.
- CompanyBiodesix
Diagnostic testing company listed on Nasdaq (BDSX).


